Form 4: NEOGENOMICS Director David Brian Perez Reports Significant Equity Transactions, Including RSU Vesting and New Option Grants
Insider Transaction Report
NEOGENOMICS Director David Brian Perez reported the vesting of 12,254 restricted stock units into common stock and the acquisition of new stock options and restricted stock units on June 1, 2025, increasing his direct common stock holdings to 33,890 shares.
Summary
- David Brian Perez, a Director at NEOGENOMICS INC (NEO), reported equity transactions on June 1, 2025, as detailed in a Form 4 filing.
- 12,254 Restricted Stock Units (RSUs) vested, converting into 12,254 shares of common stock at a price of $0, as previously reported on a Form 4.
- He acquired 16,107 new stock options with an exercise price of $7.28, which become exercisable from June 1, 2026, and expire on June 1, 2035.
- He also acquired 23,077 new Restricted Stock Units, which are scheduled to vest on June 1, 2026.
- Following these transactions, Mr. Perez directly holds 33,890 shares of common stock.
- Additionally, he indirectly holds 10,000 shares of common stock through the Perez Joint Revocable Trust.
- His total direct derivative holdings include 42,862 stock options (comprising 16,107 new options, 9,730 options at $7.34, 8,353 options at $14.82, and 8,672 options at $13.71) and 23,077 new Restricted Stock Units.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as the director's direct common stock holdings increased through RSU vesting and new equity grants were issued, aligning his interests with shareholders. There were no reported sales of common stock.
Positives
- Director David Brian Perez increased his direct common stock holdings by 12,254 shares through the vesting of Restricted Stock Units, aligning his interests with shareholders.
- The acquisition of 16,107 new stock options and 23,077 new Restricted Stock Units indicates continued equity-based compensation and long-term alignment of the director's incentives with company performance.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- 10,000 shares of common stock are indirectly beneficially owned through the Perez Joint Revocable Trust, which is a related party.
Stakeholder Impact
- Shareholders: The increase in a director's direct common stock holdings and the grant of new equity awards can be viewed positively as it aligns management's interests with shareholder value.
Next Steps
- Vesting of 23,077 Restricted Stock Units is scheduled for June 1, 2026.
- Outstanding stock options with various exercise prices and expiration dates remain, which may be exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 2016-12-09 | Date of the Perez Joint Revocable Trust agreement. |
| 2023-06-10 | Date exercisable for 9,730 stock options with an exercise price of $7.34, expiring on June 10, 2029. |
| 2024-08-10 | Date exercisable for 8,353 stock options with an exercise price of $14.82, expiring on August 10, 2033. |
| 2025-06-01 | Transaction date for RSU vesting, acquisition of new stock options, and new RSUs. Also the date exercisable for 8,672 stock options with an exercise price of $13.71, expiring on June 1, 2034. |
| 2025-06-03 | Filing date of the SEC Form 4. |
| 2026-06-01 | Date exercisable for 16,107 new stock options and vesting date for 23,077 new Restricted Stock Units. |
| 2029-06-10 | Expiration date for 9,730 stock options with an exercise price of $7.34. |
| 2033-08-10 | Expiration date for 8,353 stock options with an exercise price of $14.82. |
| 2034-06-01 | Expiration date for 8,672 stock options with an exercise price of $13.71. |
| 2035-06-01 | Expiration date for 16,107 new stock options. |
Keywords
NEOGENOMICS, NEO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU Vesting, Director Stock Holdings, Equity Compensation, David Brian Perez
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.